-$0.49 Earnings Per Share Expected for Chimerix Inc (CMRX) This Quarter
Brokerages expect Chimerix Inc (NASDAQ:CMRX) to announce earnings of ($0.49) per share for the current quarter, according to Zacks. Three analysts have provided estimates for Chimerix’s earnings, with the lowest EPS estimate coming in at ($0.56) and the highest estimate coming in at ($0.43). Chimerix reported earnings of ($0.32) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 53.1%. The company is scheduled to announce its next quarterly earnings results on Thursday, March 1st.
According to Zacks, analysts expect that Chimerix will report full year earnings of ($1.60) per share for the current year, with EPS estimates ranging from ($1.64) to ($1.56). For the next fiscal year, analysts expect that the firm will post earnings of ($1.85) per share, with EPS estimates ranging from ($2.12) to ($1.50). Zacks’ EPS calculations are an average based on a survey of research analysts that cover Chimerix.
Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.06. Chimerix had a negative return on equity of 26.00% and a negative net margin of 1,440.67%. The company had revenue of $0.90 million for the quarter, compared to analyst estimates of $0.81 million.
In other news, insider Linda M. Richardson sold 19,833 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $4.47, for a total transaction of $88,653.51. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 4.40% of the stock is owned by insiders.
Several institutional investors have recently modified their holdings of CMRX. Rhumbline Advisers raised its position in shares of Chimerix by 7.3% during the 2nd quarter. Rhumbline Advisers now owns 48,541 shares of the biopharmaceutical company’s stock worth $265,000 after purchasing an additional 3,300 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Chimerix by 3.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 253,367 shares of the biopharmaceutical company’s stock worth $1,381,000 after purchasing an additional 8,287 shares during the last quarter. AXA raised its position in shares of Chimerix by 284.9% during the 2nd quarter. AXA now owns 258,573 shares of the biopharmaceutical company’s stock worth $1,409,000 after purchasing an additional 191,400 shares during the last quarter. Alliancebernstein L.P. raised its position in shares of Chimerix by 8.3% during the 2nd quarter. Alliancebernstein L.P. now owns 70,200 shares of the biopharmaceutical company’s stock worth $383,000 after purchasing an additional 5,400 shares during the last quarter. Finally, Teachers Advisors LLC raised its position in shares of Chimerix by 53.5% during the 2nd quarter. Teachers Advisors LLC now owns 107,179 shares of the biopharmaceutical company’s stock worth $584,000 after purchasing an additional 37,361 shares during the last quarter. Hedge funds and other institutional investors own 70.32% of the company’s stock.
Shares of Chimerix (CMRX) traded up $0.02 on Tuesday, reaching $4.92. The company’s stock had a trading volume of 141,000 shares, compared to its average volume of 272,989. Chimerix has a 12 month low of $4.17 and a 12 month high of $6.64. The stock has a market cap of $229.04, a price-to-earnings ratio of -3.44 and a beta of 1.46.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.